Royal Bank of Canada
KRYS icon

Royal Bank of Canada’s Krystal Biotech KRYS Stock Holding History

Royal Bank of Canada’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$268K Sell
1,033
-468
-31% -$125K ﹤0.01% 4530
2025
Q4 		$369K Buy
1,501
+1,103
+277% +$232K ﹤0.01% 4382
2025
Q3 		$70K Sell
398
-1,413
-78% -$211K ﹤0.01% 5679
2025
Q2 		$249K Buy
1,811
+183
+11% +$26.9K ﹤0.01% 4993
2025
Q1 		$294K Buy
1,628
+964
+145% +$162K ﹤0.01% 4410
2024
Q4 		$104K Sell
664
-2,113
-76% -$375K ﹤0.01% 5316
2024
Q3 		$506K Buy
2,777
+376
+16% +$72.5K ﹤0.01% 4088
2024
Q2 		$440K Buy
2,401
+1,377
+134% +$231K ﹤0.01% 4121
2024
Q1 		$182K Sell
1,024
-10,303
-91% -$1.43M ﹤0.01% 4771
2023
Q4 		$1.41M Buy
11,327
+4,078
+56% +$452K ﹤0.01% 3376
2023
Q3 		$841K Buy
7,249
+5,677
+361% +$693K ﹤0.01% 3572
2023
Q2 		$183K Buy
1,572
+276
+21% +$28.2K ﹤0.01% 4831
2023
Q1 		$104K Sell
1,296
-1,762
-58% -$138K ﹤0.01% 5154
2022
Q4 		$243K Buy
3,058
+2,640
+632% +$196K ﹤0.01% 4709
2022
Q3 		$29K Buy
418
+129
+45% +$9.32K ﹤0.01% 5994
2022
Q2 		$19K Sell
289
-1,243
-81% -$77.3K ﹤0.01% 6132
2022
Q1 		$102K Sell
1,532
-2,036
-57% -$127K ﹤0.01% 5634
2021
Q4 		$249K Buy
3,568
+3,171
+799% +$185K ﹤0.01% 5113
2021
Q3 		$21K Buy
397
+307
+341% +$18.2K ﹤0.01% 6679
2021
Q2 		$6K Sell
90
-1,008
-92% -$70.4K ﹤0.01% 7026
2021
Q1 		$85K Buy
1,098
+801
+270% +$58.2K ﹤0.01% 5562
2020
Q4 		$18K Buy
297
+223
+301% +$11.1K ﹤0.01% 6109
2020
Q3 		$4K Sell
74
-12
-14% -$521 ﹤0.01% 6179
2020
Q2 		$3K Buy
86
+32
+59% +$1.54K ﹤0.01% 6185
2020
Q1 		$2K Buy
+54
New +$2.82K ﹤0.01% 6303
2018
Q4 		– Sell
-11
Closed – – 6937
2018
Q3 		$0 Buy
+11
New +$185 ﹤0.01% 6827

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's KRYS Position: Q1 2026 in Review

Royal Bank of Canada reduced its Krystal Biotech (KRYS) stake by 31% in Q1 2026, selling an estimated $125K and leaving 1,033 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #4530.

Royal Bank of Canada first reported a position in KRYS in Q3 2018 and has held it in 26 quarters since. The position peaked at $1.41M in Q4 2023. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Royal Bank of Canada held 1,033 shares of Krystal Biotech worth $268K as of Q1 2026.
  • Royal Bank of Canada sold 468 Krystal Biotech shares in Q1 2026, an estimated $125K.
  • Krystal Biotech made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4530 holding.
  • Royal Bank of Canada first reported a position in Krystal Biotech in Q3 2018 and has held it in 26 quarters since.
  • Royal Bank of Canada's Krystal Biotech position peaked at $1.41M in Q4 2023.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.